First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn

 
• By Ian Schofield

The CHMP has granted a positive opinion to Celltrion’s Truxima, the first biosimilar version of Roche’s cancer treatment, MabThera, but has announced the withdrawal of two pegfilgrastim products.

Thumbs up
The CHMP has OKd the first EU biosimilar version of MabThera

More from Biosimilars

More from Biosimilars & Generics